{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-208959","form_type":"8-K","ticker":"SGHT","cik":"0001531177","company_name":"Sight Sciences, Inc.","filed_at":"2026-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.431552+00:00","generated_at":"2026-05-14T22:37:39.360989+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sight Sciences Q1 revenue up 13% to $19.7M; raises FY 2026 guidance; Alcon damages $55.4M","bullets":["Q1 revenue $19.7M (+13% YoY); net loss $13.0M ($0.24 loss per share) vs $14.2M loss in prior year.","Interventional Dry Eye revenue $1.4M (+244% YoY, +87% QoQ); Glaucoma revenue $18.3M (+7% YoY).","FY 2026 revenue guidance raised to $83M-$89M from $82M-$88M; adj. opex reaffirmed $93M-$96M.","Final Alcon judgment: $55.4M past damages + 10% ongoing royalty for Hydrus patent infringement (subject to appeal)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-208959","json":"https://secwatch.observer/filing/0001193125-26-208959.json","markdown":"https://secwatch.observer/filing/0001193125-26-208959.md","text":"https://secwatch.observer/filing/0001193125-26-208959.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1531177/000119312526208959/0001193125-26-208959-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1531177/000119312526208959/sght-20260506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T22:37:39.360989+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"289f0bc7e0abe45414651684c28ecb9a01dbf8bd","claim":"Sight Sciences, Inc. reported the first quarter ended March 31, 2026 results: revenue $19.7 million, net income Net loss was $13.0 million, EPS loss of $0.24 per share. Guidance raised.","evidence_excerpt":"results for the first quarter ended March 31, 2026 and raised its revenue guidance for full year 2026. Recent Financial and Business Highlights • Generated total revenue of $19.7 million in the first quarter of 2026, an increase of 13% compared to the same period in the prior year. • Drove Interventional Glaucoma revenue growth of 7% in the first quarter of 2026,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1531177/000119312526208959/0001193125-26-208959-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Revenue","value":"$19.7 million"},{"label":"Net income","value":"Net loss was $13.0 million"},{"label":"EPS","value":"loss of $0.24 per share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}